Spineway (ALSPW) Q2 2024 TU earnings summary

Executive summary

• Achieved first-half 2024 revenue of €6.5 million, reflecting 20% organic growth year-over-year.

• Growth driven by strong performance in Europe and Latin America, with no changes in business scope.

• Maintained stable cash position due to sales momentum and prior cost-cutting measures.

Financial highlights

• Q2 2024 revenue reached €3.47 million, up 14% compared to Q2 2023.

• H1 2024 revenue totaled €6.54 million, up from €5.43 million in H1 2023.

• Organic growth rate accelerated from 12% in H1 2023 to 20% in H1 2024.

Outlook and guidance

• Continued regulatory investments to secure new export approvals and CE/MDR certifications.

• Growth trajectory since 2021 expected to continue, with focus on high-potential markets.